Lifileucel (Amtagvi®, Iovance Biotherapeutics, San Carlos, CA, USA) is an autologous unselected TIL product, which was most recently Food and Drug Administration (FDA)-approved as a standard-of-care therapy in patients with advanced melanoma who were previously treated with a programmed death-1 (PD-1) blocking antibody and a BRAF inhibitor +/− MEK inhibitor if BRAF V600 mutation-positive. The gene discussed is BRAF; the disease is melanoma.